New insights for development of a safe and protective RSV vaccine

scientific article

New insights for development of a safe and protective RSV vaccine is …
instance of (P31):
scholarly articleQ13442814
review articleQ7318358

External links are
P356DOI10.4161/HV.6.6.11562
P932PMC publication ID2965816
P698PubMed publication ID20671419
P5875ResearchGate publication ID45424151

P50authorGregory PrinceQ5607119
Jorge C BlancoQ55193786
Stefanie N. VogelQ92126561
Kari Ann ShireyQ115088605
Marina BoukhvalovaQ123569133
P2860cites workRespiratory virus infections after marrow transplant: the Fred Hutchinson Cancer Research Center experienceQ45741859
Pulmonary lesions in primary respiratory syncytial virus infection, reinfection, and vaccine-enhanced disease in the cotton rat (Sigmodon hispidus).Q45746077
Respiratory syncytial virus pneumonia among the elderly: an assessment of disease burdenQ45752482
Host genetic determinants of vaccine-induced eosinophilia during respiratory syncytial virus infectionQ45752590
A bovine model of vaccine enhanced respiratory syncytial virus pathophysiologyQ45754571
Safety and immunogenicity of a purified F protein respiratory syncytial virus (PFP-2) vaccine in seropositive children with bronchopulmonary dysplasiaQ45757916
Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virusQ45759631
Respiratory syncytial virus infection in infants is associated with predominant Th-2-like responseQ45761593
A human respiratory syncytial virus (RSV) primate model of enhanced pulmonary pathology induced with a formalin-inactivated RSV vaccine but not a recombinant FG subunit vaccineQ45773865
Asthma and immunoglobulin E antibodies after respiratory syncytial virus bronchiolitis: a prospective cohort study with matched controlsQ45786507
Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric populationQ45823296
Respiratory virus immunization. I. A field trial of two inactivated respiratory virus vaccines; an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccineQ45823297
Immunoprophylaxis and immunotherapy of respiratory syncytial virus infection in the cotton rat.Q45828600
Cytotoxic T cell specificity for respiratory syncytial virus proteins: fusion protein is an important target antigenQ45831199
An outbreak of respiratory syncytial virus in a bone marrow transplant centerQ45866494
Respiratory-syncytial-virus infections, reinfections and immunity. A prospective, longitudinal study in young childrenQ45888997
Evaluation of BBG2Na in infant macaques: specific immune responses after vaccination and RSV challengeQ47435138
TLR4 agonists as immunomodulatory agentsQ50076068
Purification and structural determination of nontoxic lipid A obtained from the lipopolysaccharide of Salmonella typhimurium.Q50213048
Bronchiolitis-associated hospitalizations among US children, 1980-1996.Q50653027
IL-9 regulates pathology during primary and memory responses to respiratory syncytial virus infection.Q51889027
CD14-dependent and CD14-independent signaling pathways in murine macrophages from normal and CD14 knockout mice stimulated with lipopolysaccharide or taxol.Q52525157
Comparison of cytokine responses in nasopharyngeal aspirates from children with viral lower respiratory tract infections.Q53051358
A potential molecular mechanism for hypersensitivity caused by formalin-inactivated vaccinesQ56689869
Experimental RS virus infection of cotton rats. A viral and immunofluorescent studyQ70657671
Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. The PREVENT Study GroupQ71958863
Requirement for STAT1 in LPS-induced gene expression in macrophagesQ73778456
MD-2 binds to bacterial lipopolysaccharideQ74355716
Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study GroupQ77300551
MD-2, a molecule that confers lipopolysaccharide responsiveness on Toll-like receptor 4Q22009943
TLR4 mutations are associated with endotoxin hyporesponsiveness in humansQ22254186
Defective LPS Signaling in C3H/HeJ and C57BL/10ScCr Mice: Mutations in Tlr4 GeneQ22299417
Genetic and Physical Mapping of theLpsLocus: Identification of the Toll-4 Receptor as a Candidate Gene in the Critical RegionQ22337434
Crystal structure of the TLR4-MD-2 complex with bound endotoxin antagonist EritoranQ24292781
The structural basis of lipopolysaccharide recognition by the TLR4-MD-2 complexQ24316449
Resistance to endotoxin shock and reduced dissemination of gram-negative bacteria in CD14-deficient miceQ24329114
Toll-like receptor signallingQ24570126
Activation of innate immune antiviral responses by Nod2Q24646833
Th2 cytokines and asthma. Interleukin-9 as a therapeutic target for asthmaQ24791881
Neutralization epitopes of the F glycoprotein of respiratory syncytial virus: effect of mutation upon fusion functionQ27486621
Crystal structures of human MD-2 and its complex with antiendotoxic lipid IVaQ27645881
Alternative activation of macrophagesQ27860939
Toll-like receptors: critical proteins linking innate and acquired immunityQ29615190
CD11b/CD18 acts in concert with CD14 and Toll-like receptor (TLR) 4 to elicit full lipopolysaccharide and taxol-inducible gene expressionQ31725312
Severe respiratory syncytial virus bronchiolitis in infants is associated with reduced airway interferon gamma and substance P.Q33302897
Immunoprophylaxis with palivizumab, a humanized respiratory syncytial virus monoclonal antibody, for prevention of respiratory syncytial virus infection in high risk infants: a consensus opinionQ33545548
Differential role for TLR3 in respiratory syncytial virus-induced chemokine expression.Q33737766
Respiratory syncytial virus (RSV) SH and G proteins are not essential for viral replication in vitro: clinical evaluation and molecular characterization of a cold-passaged, attenuated RSV subgroup B mutantQ33738521
Monophosphoryl lipid A (MPL) formulations for the next generation of vaccinesQ33753562
RSV fusion (F) protein DNA vaccine provides partial protection against viral infectionQ33775390
Priming with secreted glycoprotein G of respiratory syncytial virus (RSV) augments interleukin-5 production and tissue eosinophilia after RSV challengeQ33783066
Involvement of toll-like receptor 4 in innate immunity to respiratory syncytial virusQ33848810
Plasmid DNA encoding the respiratory syncytial virus G protein is a promising vaccine candidateQ33895116
Activation of interferon response through toll-like receptor 3 impacts viral pathogenesis and pulmonary toll-like receptor expression during respiratory syncytial virus and influenza infections in the cotton rat Sigmodon hispidus modelQ33901537
Respiratory syncytial virus infection in adultsQ33961877
Respiratory syncytial virus infection in inbred miceQ34098698
DNA immunization against respiratory syncytial virus (RSV) in infant rhesus monkeysQ43444618
A novel bipolar mode of attachment to aluminium-containing adjuvants by BBG2Na, a recombinant subunit hRSV vaccineQ43534761
Priming immunization determines T helper cytokine mRNA expression patterns in lungs of mice challenged with respiratory syncytial virusQ43852460
Interleukin-4 and interleukin-13 signaling connections mapsQ44469051
Peripheral blood mononuclear cells from infants hospitalized because of respiratory syncytial virus infection express T helper-1 and T helper-2 cytokines and CC chemokine messenger RNA.Q45106083
Antibody affinity maturation and respiratory syncytial virus diseaseQ45383013
Respiratory syncytial virus decreases p53 protein to prolong survival of airway epithelial cells.Q45401032
Severe human lower respiratory tract illness caused by respiratory syncytial virus and influenza virus is characterized by the absence of pulmonary cytotoxic lymphocyte responsesQ45406272
The TLR4 agonist, monophosphoryl lipid A, attenuates the cytokine storm associated with respiratory syncytial virus vaccine-enhanced disease.Q45417025
Lipopolysaccharide hyporesponsiveness as a risk factor for intensive care unit hospitalization in infants with respiratory syncitial virus bronchiolitisQ45418783
Respiratory syncytial virus (RSV) infection induces cyclooxygenase 2: a potential target for RSV therapy.Q45495234
Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infantsQ45504141
Association between common Toll-like receptor 4 mutations and severe respiratory syncytial virus diseaseQ45640302
The role of Toll-like receptor 4 versus interleukin-12 in immunity to respiratory syncytial virusQ45658652
Type 1 and type 2 cytokine imbalance in acute respiratory syncytial virus bronchiolitisQ45723418
Immunogenicity of a new purified fusion protein vaccine to respiratory syncytial virus: a multi-center trial in children with cystic fibrosisQ45723625
Association of cytokine responses with disease severity in infants with respiratory syncytial virus infectionQ45730272
Respiratory syncytial virus-induced activation of nuclear factor-kappaB in the lung involves alveolar macrophages and toll-like receptor 4-dependent pathwaysQ45730326
The role of IFN in respiratory syncytial virus pathogenesisQ45733409
Vaccine-enhanced respiratory syncytial virus disease in cotton rats following immunization with Lot 100 or a newly prepared reference vaccineQ45734744
Macrophage inflammatory protein-1alpha (not T helper type 2 cytokines) is associated with severe forms of respiratory syncytial virus bronchiolitisQ45736349
Local interferon-gamma levels during respiratory syncytial virus lower respiratory tract infection are associated with disease severityQ45736571
Monophosphoryl lipid A adjuvant reverses a principal histologic parameter of formalin-inactivated respiratory syncytial virus vaccine-induced diseaseQ45738401
Bronchiolitis-associated mortality and estimates of respiratory syncytial virus-associated deaths among US children, 1979-1997.Q45739727
Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virusQ45739890
Type 1-like immune response is found in children with respiratory syncytial virus infection regardless of clinical severityQ45740483
Role of interferon gamma in the pathogenesis of primary respiratory syncytial virus infection in BALB/c miceQ45740485
DNA encoding the attachment (G) or fusion (F) protein of respiratory syncytial virus induces protection in the absence of pulmonary inflammationQ45740607
Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccineQ34206177
Immunoprotective activity and safety of a respiratory syncytial virus vaccine: mucosal delivery of fusion glycoprotein with a CpG oligodeoxynucleotide adjuvantQ34226850
Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus diseaseQ34330690
Respiratory syncytial virus infection in elderly and high-risk adultsQ34414401
Lipopolysaccharide and monophosphoryl lipid A differentially regulate interleukin-12, gamma interferon, and interleukin-10 mRNA production in murine macrophages.Q35552804
Intravenous immunoglobulin treatment of respiratory syncytial virus infections in infants and young childrenQ35562475
Review of epidemiology and clinical risk factors for severe respiratory syncytial virus (RSV) infectionQ35582849
IL-13 is associated with reduced illness and replication in primary respiratory syncytial virus infection in the mouseQ35665094
TLRs: differential adapter utilization by toll-like receptors mediates TLR-specific patterns of gene expressionQ35679602
Respiratory syncytial virus-induced immunoprotection and immunopathologyQ35882894
The pathogenesis of respiratory syncytial virus infection in cotton ratsQ36058867
Endotoxin-tolerant mice have mutations in Toll-like receptor 4 (Tlr4)Q36367812
A role for immune complexes in enhanced respiratory syncytial virus diseaseQ36371267
Eliminating a region of respiratory syncytial virus attachment protein allows induction of protective immunity without vaccine-enhanced lung eosinophilia.Q36400958
Atypical pulmonary eosinophilia is mediated by a specific amino acid sequence of the attachment (G) protein of respiratory syncytial virusQ36401291
Resistance to respiratory syncytial virus (RSV) challenge induced by infection with a vaccinia virus recombinant expressing the RSV M2 protein (Vac-M2) is mediated by CD8+ T cells, while that induced by Vac-F or Vac-G recombinants is mediated by antQ36691093
Enhancement of respiratory syncytial virus pulmonary pathology in cotton rats by prior intramuscular inoculation of formalin-inactiva ted virusQ36858777
Quantitative aspects of passive immunity to respiratory syncytial virus infection in infant cotton ratsQ36903965
Respiratory syncytial virus activates innate immunity through Toll-like receptor 2.Q37051620
Mechanisms of immunity to respiratory syncytial virus in cotton ratsQ37103582
Isolation of an endotoxin-MD-2 complex that produces Toll-like receptor 4-dependent cell activation at picomolar concentrationsQ37356770
Expression of the F glycoprotein of respiratory syncytial virus by a recombinant vaccinia virus: comparison of the individual contributions of the F and G glycoproteins to host immunityQ37401975
Challenges in developing a pediatric RSV vaccineQ37531753
Nucleotide sequence of the gene encoding the fusion (F) glycoprotein of human respiratory syncytial virusQ37579808
Regulation of gene expression in mouse macrophages stimulated with bacterial CpG-DNA and lipopolysaccharide.Q38359641
Association of TLR4 polymorphisms with symptomatic respiratory syncytial virus infection in high-risk infants and young childrenQ38430750
Efficacy and safety studies of a recombinant chimeric respiratory syncytial virus FG glycoprotein vaccine in cotton ratsQ39585262
Expression of respiratory syncytial virus-induced chemokine gene networks in lower airway epithelial cells revealed by cDNA microarraysQ39604025
Retinoic acid-inducible gene I mediates early antiviral response and Toll-like receptor 3 expression in respiratory syncytial virus-infected airway epithelial cellsQ40208138
Analysis of TLR4 polymorphic variants: new insights into TLR4/MD-2/CD14 stoichiometry, structure, and signalingQ40265496
Role for innate IFNs in determining respiratory syncytial virus immunopathologyQ40419767
Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in infancyQ40614352
Control of RSV-induced lung injury by alternatively activated macrophages is IL-4R alpha-, TLR4-, and IFN-beta-dependentQ40734229
TLR4, but not TLR2, mediates IFN-beta-induced STAT1alpha/beta-dependent gene expression in macrophages.Q40744508
Immune induction and modulation in mice following immunization with DNA encoding F protein of respiratory syncytial virusQ40780003
Th1/Th2-regulated expression of arginase isoforms in murine macrophages and dendritic cellsQ40928270
An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccineQ40940832
A prototype recombinant vaccine against respiratory syncytial virus and parainfluenza virus type 3.Q42068164
Human metapneumovirus: enhanced pulmonary disease in cotton rats immunized with formalin-inactivated virus vaccine and challenged.Q42428474
Inhibition of toll-like receptor 7- and 9-mediated alpha/beta interferon production in human plasmacytoid dendritic cells by respiratory syncytial virus and measles virusQ42723106
P433issue6
P921main subjectvaccineQ134808
P304page(s)482-492
P577publication date2010-06-01
P1433published inHum VaccinQ15755183
P1476titleNew insights for development of a safe and protective RSV vaccine
P478volume6

Reverse relations

cites work (P2860)
Q37368692A Minimum Epitope Overlap between Infections Strongly Narrows the Emerging T Cell Repertoire.
Q34401644A prospective, open-label, non-comparative study of palivizumab prophylaxis in children at high risk of serious respiratory syncytial virus disease in the Russian Federation
Q38733975Advances in Antiviral Therapies Targeting Toll-like Receptors
Q38130514Advances in and the potential of vaccines for respiratory syncytial virus
Q34484085Agents that increase AAM differentiation blunt RSV-mediated lung pathology
Q41721418An insect cell derived respiratory syncytial virus (RSV) F nanoparticle vaccine induces antigenic site II antibodies and protects against RSV challenge in cotton rats by active and passive immunization
Q47562812Blocking of opioid receptors in experimental formaline-inactivated respiratory syncytial virus (FI-RSV) immunopathogenesis: from beneficial to harmful impacts
Q39393694Burden of respiratory syncytial virus infection in young children
Q36977881Cell-mediated immune responses to respiratory syncytial virus infection: magnitude, kinetics, and correlates with morbidity and age
Q35615024Contributions of humoral and cellular immunity to vaccine-induced protection in humans.
Q38919640CpG in Combination with an Inhibitor of Notch Signaling Suppresses Formalin-Inactivated Respiratory Syncytial Virus-Enhanced Airway Hyperresponsiveness and Inflammation by Inhibiting Th17 Memory Responses and Promoting Tissue-Resident Memory Cells i
Q33881536Effects of anti-g and anti-f antibodies on airway function after respiratory syncytial virus infection
Q47553316Establishing Correlates of Protection for Vaccine Development: Considerations for the Respiratory Syncytial Virus Vaccine Field
Q35488618Host proteome correlates of vaccine-mediated enhanced disease in a mouse model of respiratory syncytial virus infection
Q28486995Hsp90 inhibitors exhibit resistance-free antiviral activity against respiratory syncytial virus
Q26822938Human Metapneumovirus: lessons learned over the first decade
Q33887642Human metapneumovirus virus-like particles induce protective B and T cell responses in a mouse model
Q38068065Influenza and respiratory syncytial virus (RSV) vaccines for infants: safety, immunogenicity, and efficacy
Q35690781Mammalian Cell-Derived Respiratory Syncytial Virus-Like Particles Protect the Lower as well as the Upper Respiratory Tract
Q33751615Natural killer T cell sensitization during neonatal respiratory syncytial virus infection induces eosinophilic lung disease in re-infected adult mice
Q37086092Neonatal immunization with respiratory syncytial virus glycoprotein fragment induces protective immunity in the presence of maternal antibodies in mice
Q40702974Novel HLA-A2-restricted human metapneumovirus epitopes reduce viral titers in mice and are recognized by human T cells
Q34999938Novel drugs targeting Toll-like receptors for antiviral therapy
Q34796481Optimization of potent and selective quinazolinediones: inhibitors of respiratory syncytial virus that block RNA-dependent RNA-polymerase complex activity
Q37945230Pattern recognition receptors and the innate immune response to viral infection
Q38018768Pattern recognition receptors for respiratory syncytial virus infection and design of vaccines
Q38206841Prevention and prophylaxis of respiratory syncytial virus in pediatric cardiology: a UK perspective.
Q37841269Prevention of serious respiratory syncytial virus-related illness. I: Disease pathogenesis and early attempts at prevention
Q35887649Protection conferred by virus-like particle vaccines against respiratory syncytial virus infection in mice by intranasal vaccination
Q36464016Proteomic contributions to our understanding of vaccine and immune responses
Q45364295RSV 2010: Recent advances in research on respiratory syncytial virus and other pneumoviruses
Q34506016Respiratory syncytial virus fusion glycoprotein expressed in insect cells form protein nanoparticles that induce protective immunity in cotton rats
Q39719279Respiratory syncytial virus prevention in children with congenital heart disease: who and how?
Q56893551Respiratory syncytial virus vaccine development
Q38079432Respiratory syncytial virus: current progress in vaccine development
Q38508568Role of the lipoxygenase pathway in RSV-induced alternatively activated macrophages leading to resolution of lung pathology.
Q43625547Safety and immunogenicity of a Sf9 insect cell-derived respiratory syncytial virus fusion protein nanoparticle vaccine
Q40408421Selective evolution of Toll-like receptors 3, 7, 8, and 9 in bats
Q37328584Targeting RSV with vaccines and small molecule drugs
Q43788138The cotton rat (Sigmodon hispidus) as an animal model for respiratory tract infections with human pathogens
Q40933366The preventive effect of vaccine prophylaxis on severe respiratory syncytial virus infection: A meta-analysis.
Q38167718Unmet needs in respiratory diseases : "You can't know where you are going until you know where you have been"--Anonymous
Q64102227Unveiling Integrated Functional Pathways Leading to Enhanced Respiratory Disease Associated With Inactivated Respiratory Syncytial Viral Vaccine
Q61804920Vaccine containing G protein fragment and recombinant baculovirus expressing M2 protein induces protective immunity to respiratory syncytial virus

Search more.